:. .. Analyse-univariée,

C. De-kaplan-meier and :. .. ,

:. .. Analyse-multivariée,

:. .. Réponse-au-traitement,

.. .. Discussion,

I. , Rôle de l'expression PDL1 sur la survie globale et la survie sans progression

:. .. Sur-la-survie-globale,

, 47 1. Facteurs influençant la survie globale et la survie sans progression

. Iii and :. .. Limites,

:. .. Les,

:. .. Intérêts-de-l'étude,

. Iv, . Conséquences, and :. .. Perspectives,

.. .. Conclusion,

.. .. Bibliographie,

. .. Annexes,

J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, issue.5, pp.359-86, 2015.

, chiffres -Cancer du poumon | Institut National Du Cancer, Jul30, 2017.

C. Locher, D. Debieuvre, D. Coëtmeur, F. Goupil, O. Molinier et al., Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies

C. Locher, L. Falchero, and C. Dujon, KBP-2010-CPHG: Characteristics and management of 6,083 new cases of non-small-cell-lung-cancer (NSCLC), Eur Respir J, vol.40, issue.Suppl56, p.3128, 2012.

M. B. Beasley, E. Brambilla, and W. D. Travis, The 2004 World Health Organization classification of lung tumors, Seminars in Roentgenology, vol.40, 2005.

W. B. Coley, The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc R Soc Med, vol.3, pp.1-48, 1910.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, p.646, 2011.

D. S. Chen and I. Mellman, Oncology meets immunology: the cancer-immunity cycle, Immunity, vol.39, issue.1, pp.1-10, 2013.

M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, PD-1 and Its Ligands in Tolerance and Immunity, Annu Rev Immunol, vol.26, issue.1, pp.677-704, 2008.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012.

D. S. Chen, B. A. Irving, and F. S. Hodi, Molecular pathways: next-generation immunotherapy

S. L. Topalian, C. G. Drake, and D. M. Pardoll, Targeting the PD-1/B7-H1(PD-L1) pathway to activateanti-tumor immunity, Curr Opin Immunol, vol.24, issue.2, pp.207-219, 2012.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versusDocetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, 652015.

R. S. Herbst, P. Baas, and D. W. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, and A. G. Robinson, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

J. Adam, D. Planchard, A. Marabelle, J. C. Soria, J. Y. Scoazec et al., Évaluation de l'expression de PD-L1 en immunohistochimie : un biomarqueur émergent dans les carcinomes pulmonaires non à petites cellules, Ann Pathol, vol.36, issue.1, pp.94-102, 2016.
DOI : 10.1016/j.annpat.2015.11.004

J. Annoncol-;-adam, L. Stang, N. Rouquette, I. Cazes, A. Badoual et al., Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, vol.29, pp.953-958, 2018.

F. R. Hirsch, A. Mcelhinny, and D. Stanforth, PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the « Blueprint PD-L1 IHC Assay Comparison Project, J Thorac Oncol, vol.12, p.1, 2016.

P. N. Aguiar, I. L. Santoro, H. Tadokoro, G. De-lima-lopes, B. A. Filardi et al., A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker, Immunotherapy, vol.8, issue.9, pp.1011-1020, 2016.

-. Has-haute-autorité-de-santé and . Opdivo-cbnpc-non-Épidermoïde,

-. Has-haute-autorité-de-santé and . Opdivo-cbnpc-non-Épidermoïde, Mis en ligne le 30

K. M. Kerr, M. Tsao, A. G. Nicholson, Y. Yatabe, I. I. Wistuba et al., Programmed death-ligand 1 immunohis-tochemistry in lung cancer: in what state is this art?, JThorac Oncol, vol.10, pp.985-994, 2015.

L. Bracci, G. Schiavoni, A. Sistigu, and F. Belardelli, Immune-based mechanisms of cytotoxic chemotherapy: implicationsfor the design of novel and rationale-based combined treat-ments against cancer, Cell Death Differ, vol.21, pp.15-25, 2014.

P. N. Aguiar, , vol.8, pp.479-88, 2016.

, The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

J. Souquet, P. Fournel, N. Girard, and D. , Moro-Sibilo immunotherapy dans les CBNPC, 2017.

T. Shukuya and D. P. Carbone, Predictive markers for the efficacy of antiPD1/PDL1 antibodies in lung cancer, J Thorac Oncol, vol.11, pp.976-88, 2016.

J. Corny, A. Costantini, and V. Fallet, Real-life use of nivolumab in non small cell lung cancer: a multicentric cohorte to determine its clinical efficacy and predictive factor of early progression, ASCO 2017, 2017.

. Asco-2017, L. Crino, P. Bidoli, and A. Delmonte, Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population, Abstract, vol.3067, 2017.

, Updated Dataset assessing Tumor Mutation Burden (TMB) as a biomarker for response to PD-1/PD-L1 Targeted Therapies in Lung Cancer ( LC) Siraj Ali and al, Foundation Medicine

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibi-ting adaptive immune resistance, Nature, vol.515, pp.568-71, 2014.
DOI : 10.1038/nature13954

URL : http://europepmc.org/articles/pmc4246418?pdf=render

G. P. Pfeifer, M. F. Denissenko, M. Olivier, N. Tretyakova, S. S. Hecht et al., Tobacco smoke carcinogens, DNA damage andp53 mutations in smoking-associated cancers, Oncogene, vol.21, issue.48, pp.7435-51, 2002.
DOI : 10.1038/sj.onc.1205803

URL : https://www.nature.com/articles/1205803.pdf

F. Penault--llorca, La charge mutationnelle. Correspondances en oncothéranostic vol VI, vol.3, 2009.

, Prise en charge des effets secondaires (digestifs et pulmonaires) au Nivolumab selon l, Annexe, vol.5